Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131144 · ClinicalTrials.gov registry record · Phase 3
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 583
- Enrollment target
NCT00131144: Completed Phase 3 study, sponsored by Novartis.
NCT00131144 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 583 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00131144, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 583 participants
- Enrollment target
Study Summary
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and progression of diabetic retinopathy, intensive control of glucose is usually not achieved in clinical practice.
Interventions
- DRUG Placebo
- DRUG Octreotide Acetate in Microspheres
- DRUG Octreotide Acetate in Microspheres 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 583 participants |
| Start Date | 1999-11 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
What the finished NCT00131144 record still lists
NCT00131144 is an interventional study that assigns participants to a tested intervention. The registered 583 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (24% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00131144 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00131144 about?
NCT00131144 is a clinical study titled "Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy". The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy. Although intensive control of blood glucose has been shown to reduce the development and p...
What is the current status of trial NCT00131144?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 583 participants. The study started on 1999-11. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00131144?
The interventions under investigation include: Placebo (DRUG), Octreotide Acetate in Microspheres (DRUG), Octreotide Acetate in Microspheres 20 mg (DRUG).
Who is sponsoring clinical trial NCT00131144?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00131144's enrollment target sits among peer trials
583 652nd of 2000 higher than 1,348 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
- NCT04984291 · 584 participants · NA
Zimmer Biomet Shoulder Arthroplasty PMCF
- NCT05983757 · 584 participants · NA
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
- NCT06569290 · 584 participants · NA
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia